NCT07330830Recruiting
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 26 Nov 2025
- Primary completion date
- 26 Nov 2027
- Lead sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07330830
What you commit to
- Study type: Observational
- Planned participants: 600
- From 26 Nov 2025 to the primary completion date, 26 Nov 2027
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of another cause of chronic liver disease, including:
- Viral hepatitis (B, C, or E)
- Primary biliary cholangitis or primary sclerosing cholangitis
- Autoimmune hepatitis
- Wilson's disease
- Hemochromatosis
- Alpha-1 antitrypsin deficiency
- Alcoholic liver disease, or daily alcohol consumption \>30 g/day for men or \>20 g/day for women
- -Pregnant women.
Age
- Patients under 18 years of age.
Other
- Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.).
Criteria the registry did not label
- IInclusion Criteria
- -Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD.
- MASLD is defined as evidence of hepatic steatosis associated with overweight/obesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria.
- Patients affiliated with, or beneficiaries of, a social security scheme.
- Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire de la Guyane Coordinator of this site? Confirm its status | Cayenne | French Guiana | Not yet recruiting |
| CHU de la Guadeloupe Coordinator of this site? Confirm its status | Pointe-à-Pitre | Guadeloupe | Recruiting |
| Centre Hospitalier Universitaire de la Réunion Coordinator of this site? Confirm its status | Saint-Denis | Réunion | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.